Workflow
Aptose Biosciences(APTO)
icon
Search documents
Aptose Biosciences(APTO) - 2023 Q3 - Quarterly Report
2023-11-08 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporatio ...
Aptose Biosciences(APTO) - 2023 Q2 - Earnings Call Transcript
2023-08-11 03:01
Aptose Biosciences Inc. (NASDAQ:APTO) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Corporate Communications and Investor Relations William Rice - Chairman, President and Chief Executive Officer Rafael Bejar - Senior Vice President and Chief Medical Officer Fletcher Payne - Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler Matthew Biegler - Oppenheimer Li Watsek - Cantor Fitzgerald Soumit Roy ...
Aptose Biosciences(APTO) - 2023 Q2 - Quarterly Report
2023-08-09 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporation or ...
Aptose Biosciences(APTO) - 2023 Q1 - Earnings Call Transcript
2023-05-09 01:22
Aptose Biosciences Inc. (NASDAQ:APTO) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Corporate Communications & Investor Relations William G. Rice – Chairman, President and Chief Executive Officer Rafael Bejar – Senior Vice President and Chief Medical Officer Fletcher Payne – Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff – Piper Sandler & Co. Li Watsek – Cantor Fitzgerald Joseph Pantginis – H.C. Wainwright Ope ...
Aptose Biosciences(APTO) - 2023 Q1 - Quarterly Report
2023-05-07 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporation or ...
Aptose Biosciences(APTO) - 2022 Q4 - Earnings Call Transcript
2023-03-24 02:07
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2022 Earnings Conference Call March 23, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director William Rice - Chairman, President and CEO Fletcher Payne - SVP and Chief Financial Officer Rafael Bejar - SVP and Chief Medical Officer Conference Call Participants Matthew Biegler - Oppenheimer Soumit Roy - Jones Trading Joe Pantginis - H.C. Wainwright Edward Tenthoff - Piper Sandler Operator Hello and thank you for standing by and welcome to Aptose Bi ...
Aptose Biosciences(APTO) - 2022 Q4 - Annual Report
2023-03-23 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3200 Aptose Biosciences Inc. (Exact name of Registrant as specified in its Charter) Canada 98-1136802 (State or other jurisdiction of ...
Aptose Biosciences(APTO) - 2022 Q3 - Earnings Call Transcript
2022-11-01 23:52
Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2022 Results Conference Call November 1, 2022 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director William Rice - Chairman, President and CEO Fletcher Payne - SVP and Chief Financial Officer Rafael Bejar - SVP and Chief Medical Officer Conference Call Participants Li Watsek - Cantor Fitzgerald Soumit Roy - Jones Trading John Newman - Canaccord Genuity Matthew Biegler - Oppenheimer Joe Pantginis - H.C. Wainwright Edward Tenthoff - Piper Sandler Operat ...